Access and payment now go hand-in-hand with clinical trials in creating a successful drug launch.
“In terms of the general launch environment, access requirements have increased dramatically, and that’s affected our whole approach. We’ve had to get more sophisticated in preparing for access, so we work on it in more depth and start thinking about it as early as Phase II, including trial design.” [Arnout Ploos van Amstel (Novartis), quoted in the McKinsey white paper Why Innovative Products Aren’t Enough for a Successful Parma Launch.]
“In terms of the general launch environment, access requirements have increased dramatically, and that’s affected our whole approach. We’ve had to get more sophisticated in preparing for access, so we work on it in more depth and start thinking about it as early as Phase II, including trial design.” [Arnout Ploos van Amstel (Novartis), quoted in the McKinsey white paper Why Innovative Products Aren’t Enough for a Successful Parma Launch.]
Attend the PayerSpace Conference to learn how companies with drugs from early stage to clinical trials can benefit from an understanding of payers and payer communications.
- Which payers are key to my success?
- How do drug and pharmacy benefits work, and which one will apply to my product?
- What is a Pharmacy and Therapeutics Committee, and how does drug assessment and evaluation impact my development process?
- How do successful firms communicate with payers through account management, health outcomes and economics research, and medical affairs?